These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 8222254)
1. Serum tumor markers for patient monitoring: a case-oriented approach illustrated with carcinoembryonic antigen. Fritsche HA Clin Chem; 1993 Nov; 39(11 Pt 2):2431-4. PubMed ID: 8222254 [TBL] [Abstract][Full Text] [Related]
2. Individual cutoff levels of carcinoembryonic antigen and CA 242 indicate recurrence of colorectal cancer with high sensitivity. Engarås B Dis Colon Rectum; 2003 Mar; 46(3):313-21. PubMed ID: 12626905 [TBL] [Abstract][Full Text] [Related]
3. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347 [TBL] [Abstract][Full Text] [Related]
4. The use of prognostic markers in surgery for colorectal cancer. Northover J Eur J Cancer; 1995; 31A(7-8):1207-9. PubMed ID: 7577022 [TBL] [Abstract][Full Text] [Related]
5. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Dombernowsky P Clin Chem; 1996 Apr; 42(4):564-75. PubMed ID: 8605674 [TBL] [Abstract][Full Text] [Related]
6. Concordance of Carcinoembryonic Antigen Ratio and Response Evaluation Criteria in Solid Tumors as Prognostic Surrogate Indicators of Metastatic Colorectal Cancer Patients Treated with Chemotherapy. Huang SC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Lin CC; Jiang JK; Chang SC Ann Surg Oncol; 2015 Jul; 22(7):2262-8. PubMed ID: 25586242 [TBL] [Abstract][Full Text] [Related]
7. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221 [TBL] [Abstract][Full Text] [Related]
9. Tumor-associated glycoprotein-72 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma. A longitudinal study. Guadagni F; Roselli M; Amato T; Cosimelli M; Mannella E; Perri P; Abbolito MR; Cavaliere R; Colcher D; Greiner JW Cancer; 1991 Dec; 68(11):2443-50. PubMed ID: 1933781 [TBL] [Abstract][Full Text] [Related]
10. Improved tumour marker sensitivity in detecting colorectal liver metastases by combined type IV collagen and CEA measurement. Nyström H; Tavelin B; Björklund M; Naredi P; Sund M Tumour Biol; 2015 Dec; 36(12):9839-47. PubMed ID: 26162539 [TBL] [Abstract][Full Text] [Related]
11. Dynamic assessment of carcinoembryonic antigen in the first month after liver resection for colorectal liver metastases as a rapid-recurrence predictor. Takamoto T; Sugawara Y; Hashimoto T; Shimada K; Inoue K; Maruyama Y; Makuuchi M J Surg Oncol; 2016 Mar; 113(4):463-8. PubMed ID: 27100029 [TBL] [Abstract][Full Text] [Related]
12. Combined measurement of hepatocyte growth factor and carcinoembryonic antigen as a prognostic marker for patients with dukes a and B colorectal cancer: results of a five-year study. Miki C; Inoue Y; Hiro J; Ojima E; Araki T; Uchida K; Kusunoki M Dis Colon Rectum; 2006 Nov; 49(11):1710-8. PubMed ID: 16990975 [TBL] [Abstract][Full Text] [Related]
13. Monitoring of circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer. Pesta M; Fichtl J; Kulda V; Topolcan O; Treska V Anticancer Res; 2013 May; 33(5):2239-43. PubMed ID: 23645782 [TBL] [Abstract][Full Text] [Related]
14. Plasma prolactin in patients with colorectal cancer. Value in follow-up and as a prognosticator. Patel DD; Bhatavdekar JM; Ghosh N; Vora HH; Karelia NH; Shah NG; Suthar TP; Balar DB; Trivedi CR Cancer; 1994 Feb; 73(3):570-4. PubMed ID: 8299078 [TBL] [Abstract][Full Text] [Related]
15. Serum haptoglobin as a novel molecular biomarker predicting colorectal cancer hepatic metastasis. Sun L; Hu S; Yu L; Guo C; Sun L; Yang Z; Qi J; Ran Y Int J Cancer; 2016 Jun; 138(11):2724-31. PubMed ID: 26756179 [TBL] [Abstract][Full Text] [Related]
16. Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases. Peltonen R; Österlund P; Lempinen M; Nordin A; Stenman UH; Isoniemi H Tumour Biol; 2018 Jan; 40(1):1010428317752944. PubMed ID: 29378497 [TBL] [Abstract][Full Text] [Related]
17. Value of carcinoembryonic antigen assay in predicting hepatic metastases, local recurrence, and survival after curative resection of colorectal cancer. Kanellos I; Zacharakis E; Demetriades H; Christoforidis E; Kanellos D; Pramateftakis MG; Betsis D Surg Today; 2006; 36(10):879-84. PubMed ID: 16998681 [TBL] [Abstract][Full Text] [Related]
18. Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer. Kristiansen S; Jørgensen LM; Hansen MH; Nielsen D; Sölétormos G Biomed Res Int; 2015; 2015():986024. PubMed ID: 26339655 [TBL] [Abstract][Full Text] [Related]
19. Utility of 2-fluoro-2-deoxy-D-glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryonic antigen elevation at different levels. Liu FY; Chen JS; Changchien CR; Yeh CY; Liu SH; Ho KC; Yen TC Dis Colon Rectum; 2005 Oct; 48(10):1900-12. PubMed ID: 15991059 [TBL] [Abstract][Full Text] [Related]
20. CA 19-9 as a marker in addition to CEA to monitor colorectal cancer. Stiksma J; Grootendorst DC; van der Linden PW Clin Colorectal Cancer; 2014 Dec; 13(4):239-44. PubMed ID: 25442815 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]